טסנטריק בשילוב עם אווסטין הינו הטיפול הסטנדרטי, המוכלל בסל הבריאות, לטיפול בסרטן הפטוצלולארי לא נתיח או גרורתי, בחולים שטרם קיבלו טיפול סיסטמי למחלתם.
Tecentriq + Avastin Unresectable HCC
STUDY DESIGN
IMbrave150 is a global, multicenter, open label, phase 3 randomized trial of Atezolizumab plus Bevacizumab as compared with sorafenib in patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy.
MEDIAN OS
Tecentriq in combination with Avastin reduced the risk of death (OS) by 34%
MEDIAN PFS
Tecentriq in combination with Avastin reduced the risk of disease progression or death by 35%
ORR
Updated ORR with Atezo + Bev was approximately 30%, with more patients achieving complete response (CR; 8%)
AUTHORS CONCLUSIONS
IMbrave150 showed consistent clinically meaningful treatment benefit and safety with 12 months of additional follow-up (median FU of 15.2 months). The combination provides the longest survival seen in a front-line Phase III study in advanced HCC, confirming Atezo + Bev as a standard of care for previously untreated, unresectable HCC.
- Tecentriq+Avastin combination is recommended by international guidelines, including: ASCO, ESMO and NCCN